Search for other papers by Mônica R Gadelha in
Google Scholar
PubMed
Search for other papers by Feng Gu in
Google Scholar
PubMed
Search for other papers by Marcello D Bronstein in
Google Scholar
PubMed
Search for other papers by Thierry C Brue in
Google Scholar
PubMed
Search for other papers by Maria Fleseriu in
Google Scholar
PubMed
Search for other papers by Ilan Shimon in
Google Scholar
PubMed
Search for other papers by Aart J van der Lely in
Google Scholar
PubMed
Search for other papers by Shoba Ravichandran in
Google Scholar
PubMed
Search for other papers by Albert Kandra in
Google Scholar
PubMed
Search for other papers by Alberto M Pedroncelli in
Google Scholar
PubMed
Search for other papers by Annamaria A L Colao in
Google Scholar
PubMed
in acromegaly and can reduce disease-associated morbidity and mortality ( 7 , 8 ). Long-acting octreotide or lanreotide Autogel is the current standard of medical care for acromegaly ( 7 ). However, many patients do not achieve biochemical control
Faculté de Médecine Lyon Est, Université Lyon 1, Lyon, France
INSERM U1052; CNRS UMR5286; Cancer Research Centre of Lyon, Lyon, France
Search for other papers by Hélène Lasolle in
Google Scholar
PubMed
UFR Sciences médicales, Université de Bordeaux, Bordeaux, France
Search for other papers by Amandine Ferriere in
Google Scholar
PubMed
INSERM U1052; CNRS UMR5286; Cancer Research Centre of Lyon, Lyon, France
Centre de Pathologie et de Neuropathologie Est, Groupement Hospitalier Est, Hospices Civils de Lyon, Bron, France
Search for other papers by Alexandre Vasiljevic in
Google Scholar
PubMed
Service d’anatomo-pathologie, Hopital Pellegrin, CHU de Bordeaux, Bordeaux, France
Search for other papers by Sandrine Eimer in
Google Scholar
PubMed
Search for other papers by Marie-Laure Nunes in
Google Scholar
PubMed
UFR Sciences médicales, Université de Bordeaux, Bordeaux, France
Search for other papers by Antoine Tabarin in
Google Scholar
PubMed
surgeon ( 2 ). Medical management of acromegaly is used when surgery fails to control the disease or when surgery cannot be performed ( 3 ). First-generation long-acting somatostatin analogs (1gSRL) (octreotide LAR and lanreotide Autogel) are the most
Search for other papers by Bernardo Maia in
Google Scholar
PubMed
Neuroendocrinology Division – Instituto Estadual do Cérebro Paulo Niemeyer, Rio de Janeiro, Brazil
Endocrinology Division – Hospital Federal de Bonsucesso, Rio de Janeiro Brazil
Search for other papers by Leandro Kasuki in
Google Scholar
PubMed
Neuroendocrinology Division – Instituto Estadual do Cérebro Paulo Niemeyer, Rio de Janeiro, Brazil
Neuropatology and Molecular Genetics Laboratory – Instituto Estadual do Cérebro Paulo Niemeyer, Rio de Janeiro, Brazil
Search for other papers by Mônica R Gadelha in
Google Scholar
PubMed
, dizziness Oral octreotide formulation (46) Somatostatin receptor 2 ligand Phase 3 completed (recently FDA approved) 20–40 mg 40 mg PO twice daily 58.2 NA Gastrointestinal, blood glucose increase Paltusotine ClinicalTrials
Search for other papers by Adrian F Daly in
Google Scholar
PubMed
Search for other papers by Liliya Rostomyan in
Google Scholar
PubMed
Search for other papers by Daniela Betea in
Google Scholar
PubMed
Search for other papers by Jean-François Bonneville in
Google Scholar
PubMed
Department of Pathological Cytology and Anatomy, Foch Hospital, Paris, France
Search for other papers by Chiara Villa in
Google Scholar
PubMed
Search for other papers by Natalia S Pellegata in
Google Scholar
PubMed
Search for other papers by Beatrice Waser in
Google Scholar
PubMed
Search for other papers by Jean-Claude Reubi in
Google Scholar
PubMed
Search for other papers by Catherine Waeber Stephan in
Google Scholar
PubMed
Search for other papers by Emanuel Christ in
Google Scholar
PubMed
Search for other papers by Albert Beckers in
Google Scholar
PubMed
; in particular those with AIP mutations have a significantly lower hormonal response to first-generation, receptor subtype 2 (SST2) specific somatostatin analogs (octreotide and lanreotide) and have a decreased rate of tumor shrinkage on treatment
Search for other papers by Ravikumar Shah in
Google Scholar
PubMed
Search for other papers by Anurag R Lila in
Google Scholar
PubMed
Search for other papers by Ramteke-Swati Jadhav in
Google Scholar
PubMed
Search for other papers by Virendra Patil in
Google Scholar
PubMed
Search for other papers by Abhishek Mahajan in
Google Scholar
PubMed
Search for other papers by Sushil Sonawane in
Google Scholar
PubMed
Search for other papers by Puja Thadani in
Google Scholar
PubMed
Search for other papers by Anil Dcruz in
Google Scholar
PubMed
Search for other papers by Prathamesh Pai in
Google Scholar
PubMed
Search for other papers by Munita Bal in
Google Scholar
PubMed
Search for other papers by Subhada Kane in
Google Scholar
PubMed
Search for other papers by Nalini Shah in
Google Scholar
PubMed
Search for other papers by Tushar Bandgar in
Google Scholar
PubMed
paranasal sinuses, mandible, intracranial, maxilla, oral cavity and others. Approximately half the patients (44.1%) had evident local symptoms. Bone pain and muscle weakness were most commonly reported. Late complications of hypophosphatemia such as
Search for other papers by Marta Araujo-Castro in
Google Scholar
PubMed
Search for other papers by Héctor Pian in
Google Scholar
PubMed
Search for other papers by Ignacio Ruz-Caracuel in
Google Scholar
PubMed
Search for other papers by Alberto Acitores Cancela in
Google Scholar
PubMed
Search for other papers by Eider Pascual-Corrales in
Google Scholar
PubMed
Endoscopic Skull Base Unit, Department of Neurosurgery, Hospital Universitario HM Puerta del Sur, Madrid, Spain
Search for other papers by Víctor Rodríguez Berrocal in
Google Scholar
PubMed
were: (i) Confirmed acromegaly diagnosis (GH levels >1 ng/mL after oral glucose tolerance test (OGTT)) and fasting plasma IGF1 levels above reference ranges for age and sex ( 1 ), (ii) operated by the senior author and (iii) with a tumor size ≥10 mm
Waikato Clinical Campus, University of Auckland, Hamilton, New Zealand
Search for other papers by M S Elston in
Google Scholar
PubMed
Search for other papers by V B Crawford in
Google Scholar
PubMed
Search for other papers by M Swarbrick in
Google Scholar
PubMed
Search for other papers by M S Dray in
Google Scholar
PubMed
Search for other papers by M Head in
Google Scholar
PubMed
Search for other papers by J V Conaglen in
Google Scholar
PubMed
–3 weeks for mouth ulcers but reported no oral, inhaled or parenteral corticosteroid use. On examination, the patient was hypertensive (BP 154/74 mmHg), euphoric and grossly oedematous with bilateral pitting oedema to the mid-shins and mild facial oedema
Search for other papers by Jonathan Hazlehurst in
Google Scholar
PubMed
Search for other papers by Bernard Khoo in
Google Scholar
PubMed
Department of Medicine, Copenhagen University Hospital – Amager and Hvidovre, Hvidovre, Denmark
Search for other papers by Carolina Brito Lobato in
Google Scholar
PubMed
Search for other papers by Ibiyemi Ilesanmi in
Google Scholar
PubMed
Search for other papers by Sally Abbott in
Google Scholar
PubMed
Search for other papers by Tin Chan in
Google Scholar
PubMed
Search for other papers by Sanesh Pillai in
Google Scholar
PubMed
Search for other papers by Kate Maslin in
Google Scholar
PubMed
Imperial College Healthcare NHS Trust, St Mary’s Hospital, London, UK
Search for other papers by Sanjay Purkayastha in
Google Scholar
PubMed
Search for other papers by Barbara McGowan in
Google Scholar
PubMed
Search for other papers by Rob Andrews in
Google Scholar
PubMed
Search for other papers by Eveleigh Nicholson in
Google Scholar
PubMed
Search for other papers by Katherine McCullough in
Google Scholar
PubMed
Search for other papers by Lorraine Albon in
Google Scholar
PubMed
Search for other papers by Rachel Batterham in
Google Scholar
PubMed
Search for other papers by Georgios K Dimitriadis in
Google Scholar
PubMed
Search for other papers by Shareen Forbes in
Google Scholar
PubMed
Search for other papers by Gavin Bewick in
Google Scholar
PubMed
Search for other papers by Tricia M-M Tan in
Google Scholar
PubMed
meal test; OGTT, oral glucose tolerance test; RYGB, Roux-en-Y gastric bypass; SC, subcutaneous. In summary, there is evidence to suggest that short-acting SC octreotide and pasireotide can prevent PBH when given three times a day with meals
Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Search for other papers by Marie Reeberg Sass in
Google Scholar
PubMed
Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Department of Clinical Biochemistry, Rigshospitalet, Copenhagen, Denmark
Search for other papers by Nicolai Jacob Wewer Albrechtsen in
Google Scholar
PubMed
Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Department of Endocrinology and Nephrology, Nordsjællands University Hospital, Hillerød, Denmark
Search for other papers by Jens Pedersen in
Google Scholar
PubMed
Search for other papers by Kristine Juul Hare in
Google Scholar
PubMed
Center for Neonatal Screening, Department of Congenital Disorders, Statens Serum Institute, Copenhagen, Denmark
Search for other papers by Nis Borbye-Lorenzen in
Google Scholar
PubMed
Search for other papers by Katalin Kiss in
Google Scholar
PubMed
Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark
Search for other papers by Tina Vilsbøll in
Google Scholar
PubMed
Steno Diabetes Center Copenhagen, Gentofte, Denmark
Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Center for Clinical Metabolic Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark
Search for other papers by Filip Krag Knop in
Google Scholar
PubMed
Search for other papers by Steen Seier Poulsen in
Google Scholar
PubMed
Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Search for other papers by Niklas Rye Jørgensen in
Google Scholar
PubMed
Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Search for other papers by Jens Juul Holst in
Google Scholar
PubMed
Search for other papers by Cathrine Ørskov in
Google Scholar
PubMed
Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Search for other papers by Bolette Hartmann in
Google Scholar
PubMed
Allen HC Prentis DM Eastell R Blumsohn A . Octreotide abolishes the acute decrease in bone turnover in response to oral glucose . Journal of Clinical Endocrinology & Metabolism 2003 88 4867 – 4873 . ( https://doi.org/10.1210/jc.2002
Search for other papers by Zi-Di Xu in
Google Scholar
PubMed
Search for other papers by Wei Zhang in
Google Scholar
PubMed
Search for other papers by Min Liu in
Google Scholar
PubMed
Search for other papers by Huan-Min Wang in
Google Scholar
PubMed
Search for other papers by Pei-Pei Hui in
Google Scholar
PubMed
Search for other papers by Xue-Jun Liang in
Google Scholar
PubMed
Search for other papers by Jie Yan in
Google Scholar
PubMed
Search for other papers by Yu-Jun Wu in
Google Scholar
PubMed
Search for other papers by Yan-Mei Sang in
Google Scholar
PubMed
Search for other papers by Cheng Zhu in
Google Scholar
PubMed
Search for other papers by Gui-Chen Ni in
Google Scholar
PubMed
limitations caused severe side effects, second-line drugs have to be considered, such as the somatostatin analog octreotide, including glucagon, nifedipine and new medicines such as sirolimus, lanreotide ( 12 ). K ATP -CHI caused by mutations in the ABCC8 or